Sarepta (SRPT) Management Firm on Eteplirsen Guidance, Robert Baird Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Risk Seen for Breakthrough Designation of Sarepta (SRPT) Eteplirsen - Deutsche Bank
June 26, 2013 10:45 AM EDT(Updated - June 26, 2013 10:50 AM EDT)
Deutsche Bank analyst Robyn Karnauskas weighed in on Sarepta Therapeutic (NASDAQ: SRPT) Wednesday in response to two key controversies. Specifically, if Prosensa reaches the market first how much share can Serepta really take? Second,
what is the read-through to Serepta from yesterday's draft guidelines for Breakthrough designation?
On the first question, Karnauska said peak Eteplirsen share of 65% is achievable even if Drisapersen takes half of the market in first year and there are no switches.
On the second question, the... More
